跳至主要内容
临床试验/NCT02287493
NCT02287493已完成不适用

Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)

Universitätsklinikum Hamburg-Eppendorf1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2013年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
35
试验地点
1
主要终点
Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC)

研究概览

简要总结

In a prospective, non-interventional, monocentric observational study the pharmacokinetic properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED) will be analyzed.

详细描述

Antibiotic concentrations are measured whilst patients receive SLED for renal replacement therapy. The plasma specimens will be quantified using high Performance liquid chromatography (HPLC).

Primary endpoint:

  • Plasma levels of antiinfectives during SLED

Secondary endpoints:

  • mortality
  • length of stay at the intensive care unit (ICU) and hospital
  • clinical cure of infections

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age: 18 or older
  • patients receiving SLED and either meropenem or ceftazidim

排除标准

  • missing informed consent

结局指标

主要结局

Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC)

时间窗: days receiving SLED, up to 5 days

Plasma concentrations of meropenem or ceftazidim by the end of SLED therapy. Meropenem and ceftazidim are often used for empirical treatment also targeting for Pseudomonas aeruginosa (PSA) infections. Therefore, minimal targeted concentrations were set to the MIC of 2 mg/l for meropenem and to the MIC of 4 mg/L for ceftazidime treatment according to the breakpoints of PSA strains.

次要结局

  • Length of Stay (LOS)(minimum duration of hospital stay, maximum 1 year)
  • Mortality(minimum duration of hospital stay, maximum 1 year)
  • Number of Patients With Clinical Cure of Infections(minimum duration of hospital stay, maximum 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

PD Dr. rer. medic. Claudia Langebrake

Head Clinical Research Hospital Pharmacy

Universitätsklinikum Hamburg-Eppendorf

研究点 (1)

Loading locations...

相似试验